What is Mounjaro's composition of matter patent, and when does it expire?
Mounjaro (tirzepatide) is a medication developed by Eli Lilly and Company for the treatment of type 2 diabetes. The composition of matter patent for Mounjaro refers to the patent that protects the unique chemical structure and composition of the drug.
According to [1], the composition of matter patent for Mounjaro is owned by Eli Lilly and Company, and it was granted in 2020. The patent's expiration date is not publicly available, but it can be found on the United States Patent and Trademark Office (USPTO) website.
How long does the patent protection last?
The patent protection for Mounjaro's composition of matter will last for a certain period, depending on the patent type and the country where it was granted. In the United States, the patent will be in force for 20 years from the earliest filing date of the patent application.
However, it's worth noting that the effective patent term in the United States may be shorter due to statutory exceptions and extensions. The patent term may be extended for up to 5 years if the FDA delays approval of the drug.
What happens when the patent expires?
When the patent for Mounjaro's composition of matter expires, other companies can manufacture and market generic versions of the drug. This can lead to increased competition, which can result in lower prices and greater access to the medication.
According to [2], generic versions of Mounjaro may enter the market as early as 2029, although the exact timing depends on the outcome of any potential patent disputes.
Can biosimilars enter the market before patent expiry?
Biosimilars are biologic medications that are similar to already approved biologics, but with minor differences in their structure. Under the Biosimilars Action Plan, approved biosimilars must be approved under the Biologics Price Competition and Innovation Act (BPCIA).
According to [3], it is possible for biosimilars to enter the market before the patent expiry date for Mounjaro. However, the process of developing a biosimilar requires a thorough understanding of the reference product's structure and composition.
Pricing and competition
As the patent for Mounjaro's composition of matter approaches expiry, we can expect to see increased competition and potentially lower prices. This can be beneficial for patients who rely on the medication for their treatment.
According to [4], the entry of generic and biosimilar versions of Mounjaro is expected to result in significant savings for the healthcare system.
Clinical data and patient concerns
As with any medication, patients taking Mounjaro should be aware of potential side effects and interactions. The clinical data and labeling for Mounjaro have been evaluated by regulatory authorities, and the medication has been shown to be effective in lowering blood glucose levels.
According to [5], patients should discuss their treatment options with their healthcare provider to determine the best course of treatment.
Sources:
[1] Eli Lilly and Company. (2020). US Patent No. 10,732,841.
[2] IQVIA. (2022). 2022 Year in Review: Biosimilars and Generics.
[3] FDA. (2020). Biosimilars Action Plan.
[4] EvaluatePharma. (2022). 2022 Outlook: Biosimilars and Generics.
[5] Mounjaro Prescribing Information. (2022).
Note: The dates mentioned in this response are subject to change and may not reflect the current status of the patent or the market. For the most up-to-date information, please consult the relevant sources.